549 related articles for article (PubMed ID: 17367478)
1. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].
van Genderen PJ; Koene HR; Spong K; Overbosch D
J Travel Med; 2007; 14(2):92-5. PubMed ID: 17367478
[TBL] [Abstract][Full Text] [Related]
2. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.
Overbosch D; Schilthuis H; Bienzle U; Behrens RH; Kain KC; Clarke PD; Toovey S; Knobloch J; Nothdurft HD; Shaw D; Roskell NS; Chulay JD;
Clin Infect Dis; 2001 Oct; 33(7):1015-21. PubMed ID: 11528574
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone + proguanil: new preparation. Second-line antimalarial combination.
Prescrire Int; 2002 Oct; 11(61):131-6. PubMed ID: 12378742
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries.
Overbosch D
J Travel Med; 2003 May; 10 Suppl 1():S16-20; discussion S21-3. PubMed ID: 12737756
[TBL] [Abstract][Full Text] [Related]
5. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.
Camus D; Djossou F; Schilthuis HJ; Høgh B; Dutoit E; Malvy D; Roskell NS; Hedgley C; De Boever EH; Miller GB;
Clin Infect Dis; 2004 Jun; 38(12):1716-23. PubMed ID: 15227617
[TBL] [Abstract][Full Text] [Related]
6. Assessment of adherence to atovaquone-proguanil prophylaxis in travelers.
DePetrillo JC; Singer C; Bergagnini IA; Kolakowski P; Edwards B; Smith MA
J Travel Med; 2010; 17(4):217-20. PubMed ID: 20636593
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
Ling J; Baird JK; Fryauff DJ; Sismadi P; Bangs MJ; Lacy M; Barcus MJ; Gramzinski R; Maguire JD; Kumusumangsih M; Miller GB; Jones TR; Chulay JD; Hoffman SL;
Clin Infect Dis; 2002 Oct; 35(7):825-33. PubMed ID: 12228819
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study.
Schlagenhauf P; Johnson R; Schwartz E; Nothdurft HD; Steffen R
J Travel Med; 2009; 16(1):42-5. PubMed ID: 19192127
[TBL] [Abstract][Full Text] [Related]
9. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.
van Riemsdijk MM; Sturkenboom MC; Ditters JM; Ligthelm RJ; Overbosch D; Stricker BH
Clin Pharmacol Ther; 2002 Sep; 72(3):294-301. PubMed ID: 12235450
[TBL] [Abstract][Full Text] [Related]
10. [Malaria chemoprophylaxis: tolerance and compliance with mefloquine and proguanil/chloroquine combination in French tourists].
Carme B; Péguet C; Nevez G
Bull Soc Pathol Exot; 1997; 90(4):273-6. PubMed ID: 9479468
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers].
Camus D; Dutoit E; Masson V; Inglebert P; Delhaes L
Med Trop (Mars); 2002; 62(3):225-8. PubMed ID: 12244915
[TBL] [Abstract][Full Text] [Related]
12. Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.
Senn N; D'Acremont V; Landry P; Genton B
Am J Trop Med Hyg; 2007 Dec; 77(6):1010-4. PubMed ID: 18165513
[TBL] [Abstract][Full Text] [Related]
13. [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris].
Blondé R; Naudin J; Bigirimana Z; Holvoet L; Fenneteau O; Vitoux C; Bourdon O; Angoulvant F; Lorrot M; D'Ortenzio E; Bourrillon A; Le Bras J; Matheron S; Faye A
Arch Pediatr; 2008 Mar; 15(3):245-52. PubMed ID: 18321692
[TBL] [Abstract][Full Text] [Related]
14. [symbol: see text] Atovaquone + proguanil for malaria prophylaxis.
Drug Ther Bull; 2001 Oct; 39(10):73-5. PubMed ID: 11706518
[TBL] [Abstract][Full Text] [Related]
15. [What is the value of the combination atovaquone-proguanil for the clinician?].
Delmont J
Med Trop (Mars); 2002; 62(3):232-6. PubMed ID: 12244917
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone-proguanil for prophylaxis and treatment of malaria.
Marra F; Salzman JR; Ensom MH
Ann Pharmacother; 2003 Sep; 37(9):1266-75. PubMed ID: 12921511
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone/proguanil for the prophylaxis and treatment of malaria.
Patel SN; Kain KC
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):849-61. PubMed ID: 16307498
[TBL] [Abstract][Full Text] [Related]
18. Questionnaire-based analysis of atovaquone-proguanil compared with mefloquine in the chemoprophylaxis of malaria in non-immune Japanese travelers.
Kato T; Okuda J; Ide D; Amano K; Takei Y; Yamaguchi Y
J Infect Chemother; 2013 Feb; 19(1):20-3. PubMed ID: 22740189
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa.
Leshem E; Meltzer E; Stienlauf S; Kopel E; Schwartz E
J Travel Med; 2014; 21(2):82-5. PubMed ID: 24298915
[TBL] [Abstract][Full Text] [Related]
20. Malaria prevention in travelers.
Juckett G
Am Fam Physician; 1999 May; 59(9):2523-30, 2535-6. PubMed ID: 10323359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
